Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 514.90 |
| Open | 513.10 |
| Bid | 515.20 x 0 |
| Ask | 515.30 x 0 |
| Day's range | 513.10 - 518.90 |
| 52-week range | 400.20 - 521.90 |
| Volume | 193,014 |
| Avg. volume | 2,140,703 |
| Market cap | 1.184T |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 28.01 |
| EPS (TTM) | 18.40 |
| Earnings date | N/A |
| Forward dividend & yield | 9.10 (1.75%) |
| Ex-dividend date | 26 Mar 2021 |
| 1y target est | 326.96 |
- Motley Fool
Here's Why Altimmune Stock Is Surging Today
Shares of Altimmune (NASDAQ: ALT), a clinical-stage biopharmaceutical company, are on the move following a positive clinical readout. Investors excited about the company's potential new weight loss drug drove the stock 23% higher as of 12:34 p.m. on Wednesday. Altimmune's weight loss drug candidate, ALT-801, is a GLP-1 receptor agonist that also activates glucagon receptors.
- Globe Newswire
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 14 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginnin
- Zacks
The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric
The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric
